To keep research teams informed of the latest updates to ClinicalTrials.gov, the University at Buffalo Clinical and Translational Science Institute (CTSI) will be providing news about the ...

The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms.

The "DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. The global impact of cancer ...

CTSI Watch and Learn educational module videos are designed to increase the knowledge and performance of clinical researchers at UB and its affiliated institutions. These 5- to 15-minute videos offer ...

CNSide Diagnostics will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform’s utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell ...

The "OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Dublin, Dec. 23, 2025 (GLOBE NEWSWIRE) -- The "AI & ML in Clinical Trials: Fundamentals, Applications, and Regulatory Aspects (May 11, 2026)" training has been added to ResearchAndMarkets.com's ...

AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from ...

POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of ...

POMPANO BEACH, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of ...